Vertex Pharmaceuticals Incorporated

VRTX Healthcare Biotechnology

Vertex Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.0 billion, up 8.90% from fiscal 2024. In the quarter to June 2026, revenue grew 12.5%, EPS grew 7.96% and free cash flow grew 9.25%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years.

499.39 9.36 −1.84%
Market cap
$129.0B
P/E
28.8×
Fwd P/E
25.5×
Dividend yield
—
F-score
8/9
Altman Z
12.06
Beneish M
−2.17
Dividend safety
n/a

Vertex Pharmaceuticals Incorporated (VRTX) EV/FCF

Alert me on EV/FCF

As of 16 October 2026, Vertex Pharmaceuticals Incorporated (VRTX) trades at a EV/FCF of 31.4×. Over the past ten years it has ranged from −440× (August 2016) to 347× (November 2016); the current reading is higher than 65% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 34.4× —
FY2024 −100× —
FY2023 28.6× 77.46%
FY2022 16.1× (22.25%)
FY2021 20.7× 11.54%
FY2020 18.6× (47.90%)
FY2019 35.6× 5.05%
FY2018 33.9× (31.37%)
FY2017 49.4× (49.76%)
FY2016 98.4× —

Quarterly newest first

Period EV/FCF Change
Jun 2026 31.2× 8.69%
Mar 2026 28.7× (16.35%)
Dec 2025 34.4× 21.68%
Sep 2025 28.2× (8.77%)
42 more quarters

Against its own ten years

Low −440× High 347×
Ten-year median 25.6×
Current reading's percentile 55

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on VRTX